Abstract:Introduction Severe tricuspid valve regurgitation (TR) is associated with increased 1-year morbidity and mortality. Characterization by valve etiology (primary, secondary, and lead-associated), a classification borrowed from mitral valve disease, has not been universally shown to correlate with outcomes. Purpose Among a large, racially diverse cohort with newly identified severe TR, we aimed to 1) characterize outcomes of severe TR by etiology, and 2) assess whether unsupervised phenoclustering or supervised outcome-driven prediction trees were more effective in establishing subgroups of TR with differential clinical risk profiles. Methods We retrospectively analyzed outcomes of 5-year all-cause death and a composite of death or heart failure hospitalization (HFH) among adult patients with new severe TR identified by echocardiography between 2007 to 2018 at a large academic tertiary referral center in the United States. Patients were initially categorized by etiology of TR, including primary, secondary, and lead-associated. Second, we separately applied unsupervised hierarchical clustering to identify distinct clusters using demographics, clinical, and echo data at the time of diagnosis. Third, we applied a supervised recursive partitioning algorithm (survival trees) by each outcome to identify distinct TR subgroups. We estimated the cumulative incidence of death and composite death or HFH over 5 years by 1) etiology of TR, 2) distinct clusters, and 3) groups identified by supervised learning (prediction trees). Results Among 2,379 consecutive patients with newly identified severe TR, the median age was 70 years, 61% were female, and 40% were Black. Event rates (95% CI) were 30.9 (29.0 to 32.8) events/100 PY for death and 49.0 (45.9 to 52.2) events/100 PY for composite death or HFH over median follow-up of 1.6 years. Event rates were similarly high across TR etiology groups for both death and composite death or HFH (Figure 1). Multiple methods of unsupervised clustering did not yield distinct clusters by patient demographic and imaging characteristics. After applying supervised survival tree modeling, four phenoclusters with distinct clinical prognoses were separately identified for death and composite death or HFH (Figure 2). Variables identified to partition the cohort to discriminate both death and composite death or HFH were age, albumin, blood urea nitrogen, right ventricular contractility, and right ventricular systolic pressure (all p<0.05). Conclusions Five-year cumulative incidence of adverse events among patients with newly diagnosed severe TR was 69% for death and 80% for composite death or HFH. TR etiology did not stratify prognosis, while supervised survival tree models identified phenoclusters with distinct clinical risk. The identified subgroups of severe TR with differential outcomes offer insights towards enrichment in clinical trials of TR and risk/benefit analysis in patients undergoing TR therapies. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Abbott

Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction

Tricuspid regurgitation in acute heart failure: is there any incremental risk?

Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis

Impact of Tricuspid Regurgitation on Outcomes After Transcatheter Mitral Valve Replacement

Association of Tricuspid Regurgitation With Outcome in Acute Heart Failure

Exercise Capacity and Clinical Outcomes in Chronic Heart Failure Patients with Mild Tricuspid Regurgitation

The prevalence, predictors, and prognosis of tricuspid regurgitation in stage B and C heart failure with preserved ejection fraction

Effect of severe tricuspid regurgitation on the prognosis of patients with atrial functional mitral regurgitation: the REVEAL-AFMR registry

445 The long-term natural course of moderate tricuspid regurgitation

Tricuspid regurgitation and heart failure: the fate of treated vs. untreated cohort in the percutaneous era

Mortality and heart failure in patients with severe tricuspid regurgitation. Impact of RV volumes and function by CMR.

Clinical outcomes among distinct groups of patients with severe tricuspid valve regurgitation

Tricuspid regurgitation in the context of severe left-sided valvular disease: Patients characteristics and outcome

Dynamic evolution of tricuspid regurgitation during hospitalization in patients with acute decompensated heart failure

Association Between Functional Tricuspid Regurgitation and Mortality Following Cardiac Surgery

Mild Tricuspid Regurgitation: A Marker of Disease Burden Independently Associated with Increased Mortality

Outcomes in severe tricuspid regurgitation by CMR: when severe is too severe

Tricuspid regurgitation and in-hospital outcomes after transcatheter aortic valve replacement in high-risk patients

Prevalence and Prognostic Implications of Changes in Tricuspid Regurgitation Severity in Acute Heart Failure

Right Heart Remodeling and Outcomes in Patients With Tricuspid Regurgitation

Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study